Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line

Akira Imaizumi, Hideya Ohnishi, Akio Yamasaki, Makoto Kawamoto, Masayo Umebayashi, Takashi Morisaki, Kenichiro Hasumi

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Development of an effective therapeutic strategy for refractory pancreatic cancer must consider whether chemosensitivity can be induced in chemoresistant cells. We established a pancreatic cancer stem cell-rich cell line using TIG-1 feeder cells and leukemia inhibitory factor (LIF)-rich SNL76/7 conditioned medium. We generated a cell line, namely YNPC031312-B, following isolation of cells from the malignant ascites of a patient with gemcitabine-resistant pancreatic cancer. A YNPC031312-B-Hypoxia cell line was established by maintaining YNPC031312-B cells under tumor-like hypoxic conditions (1% O2). Both cell lines exhibited a pancreatic cancer stem cell phenotype: YNPC031312-B cells were CD24(+)CD44(-)CD133(+)epithelial cell adhesion molecule (EpCAM)(+)alkaline phosphatase(+)Octamer-binding transcription factor (OCT)3/4+and YNPC031312-B-Hypoxia cells were CD24(+)CD44(+)CD133(+)EpCAM(+). YNPC031312-B-Hypoxia cells were larger, had superior migratory ability, and higher gemcitabine sensitivity compared to YNPC031312-B cells. The use of LIF or other factors with similar bioactivity under hypoxic conditions may contribute to the phenotypic change to gemcitabine sensitivity. Our results may aid development of new therapeutic strategies targeting refractory pancreatic cancer.

元の言語英語
ページ(範囲)653-657
ページ数5
ジャーナルAnticancer research
36
発行部数2
出版物ステータス出版済み - 2 1 2016
外部発表Yes

Fingerprint

gemcitabine
Neoplastic Stem Cells
Pancreatic Neoplasms
Cell Line
Leukemia Inhibitory Factor
Cell Hypoxia
B-Lymphocytes
Octamer Transcription Factor-3
Feeder Cells
Cell Separation
Conditioned Culture Medium
Ascites
Alkaline Phosphatase
Phenotype
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Imaizumi, A., Ohnishi, H., Yamasaki, A., Kawamoto, M., Umebayashi, M., Morisaki, T., & Hasumi, K. (2016). Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. Anticancer research, 36(2), 653-657.

Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. / Imaizumi, Akira; Ohnishi, Hideya; Yamasaki, Akio; Kawamoto, Makoto; Umebayashi, Masayo; Morisaki, Takashi; Hasumi, Kenichiro.

:: Anticancer research, 巻 36, 番号 2, 01.02.2016, p. 653-657.

研究成果: ジャーナルへの寄稿記事

Imaizumi, A, Ohnishi, H, Yamasaki, A, Kawamoto, M, Umebayashi, M, Morisaki, T & Hasumi, K 2016, 'Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line', Anticancer research, 巻. 36, 番号 2, pp. 653-657.
Imaizumi A, Ohnishi H, Yamasaki A, Kawamoto M, Umebayashi M, Morisaki T その他. Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. Anticancer research. 2016 2 1;36(2):653-657.
Imaizumi, Akira ; Ohnishi, Hideya ; Yamasaki, Akio ; Kawamoto, Makoto ; Umebayashi, Masayo ; Morisaki, Takashi ; Hasumi, Kenichiro. / Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. :: Anticancer research. 2016 ; 巻 36, 番号 2. pp. 653-657.
@article{7ccccbd60076443795535c3a52381db7,
title = "Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line",
abstract = "Development of an effective therapeutic strategy for refractory pancreatic cancer must consider whether chemosensitivity can be induced in chemoresistant cells. We established a pancreatic cancer stem cell-rich cell line using TIG-1 feeder cells and leukemia inhibitory factor (LIF)-rich SNL76/7 conditioned medium. We generated a cell line, namely YNPC031312-B, following isolation of cells from the malignant ascites of a patient with gemcitabine-resistant pancreatic cancer. A YNPC031312-B-Hypoxia cell line was established by maintaining YNPC031312-B cells under tumor-like hypoxic conditions (1{\%} O2). Both cell lines exhibited a pancreatic cancer stem cell phenotype: YNPC031312-B cells were CD24(+)CD44(-)CD133(+)epithelial cell adhesion molecule (EpCAM)(+)alkaline phosphatase(+)Octamer-binding transcription factor (OCT)3/4+and YNPC031312-B-Hypoxia cells were CD24(+)CD44(+)CD133(+)EpCAM(+). YNPC031312-B-Hypoxia cells were larger, had superior migratory ability, and higher gemcitabine sensitivity compared to YNPC031312-B cells. The use of LIF or other factors with similar bioactivity under hypoxic conditions may contribute to the phenotypic change to gemcitabine sensitivity. Our results may aid development of new therapeutic strategies targeting refractory pancreatic cancer.",
author = "Akira Imaizumi and Hideya Ohnishi and Akio Yamasaki and Makoto Kawamoto and Masayo Umebayashi and Takashi Morisaki and Kenichiro Hasumi",
year = "2016",
month = "2",
day = "1",
language = "English",
volume = "36",
pages = "653--657",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line

AU - Imaizumi, Akira

AU - Ohnishi, Hideya

AU - Yamasaki, Akio

AU - Kawamoto, Makoto

AU - Umebayashi, Masayo

AU - Morisaki, Takashi

AU - Hasumi, Kenichiro

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Development of an effective therapeutic strategy for refractory pancreatic cancer must consider whether chemosensitivity can be induced in chemoresistant cells. We established a pancreatic cancer stem cell-rich cell line using TIG-1 feeder cells and leukemia inhibitory factor (LIF)-rich SNL76/7 conditioned medium. We generated a cell line, namely YNPC031312-B, following isolation of cells from the malignant ascites of a patient with gemcitabine-resistant pancreatic cancer. A YNPC031312-B-Hypoxia cell line was established by maintaining YNPC031312-B cells under tumor-like hypoxic conditions (1% O2). Both cell lines exhibited a pancreatic cancer stem cell phenotype: YNPC031312-B cells were CD24(+)CD44(-)CD133(+)epithelial cell adhesion molecule (EpCAM)(+)alkaline phosphatase(+)Octamer-binding transcription factor (OCT)3/4+and YNPC031312-B-Hypoxia cells were CD24(+)CD44(+)CD133(+)EpCAM(+). YNPC031312-B-Hypoxia cells were larger, had superior migratory ability, and higher gemcitabine sensitivity compared to YNPC031312-B cells. The use of LIF or other factors with similar bioactivity under hypoxic conditions may contribute to the phenotypic change to gemcitabine sensitivity. Our results may aid development of new therapeutic strategies targeting refractory pancreatic cancer.

AB - Development of an effective therapeutic strategy for refractory pancreatic cancer must consider whether chemosensitivity can be induced in chemoresistant cells. We established a pancreatic cancer stem cell-rich cell line using TIG-1 feeder cells and leukemia inhibitory factor (LIF)-rich SNL76/7 conditioned medium. We generated a cell line, namely YNPC031312-B, following isolation of cells from the malignant ascites of a patient with gemcitabine-resistant pancreatic cancer. A YNPC031312-B-Hypoxia cell line was established by maintaining YNPC031312-B cells under tumor-like hypoxic conditions (1% O2). Both cell lines exhibited a pancreatic cancer stem cell phenotype: YNPC031312-B cells were CD24(+)CD44(-)CD133(+)epithelial cell adhesion molecule (EpCAM)(+)alkaline phosphatase(+)Octamer-binding transcription factor (OCT)3/4+and YNPC031312-B-Hypoxia cells were CD24(+)CD44(+)CD133(+)EpCAM(+). YNPC031312-B-Hypoxia cells were larger, had superior migratory ability, and higher gemcitabine sensitivity compared to YNPC031312-B cells. The use of LIF or other factors with similar bioactivity under hypoxic conditions may contribute to the phenotypic change to gemcitabine sensitivity. Our results may aid development of new therapeutic strategies targeting refractory pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84975229471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975229471&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 653

EP - 657

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -